Identity
- Security key
- 18869
- Ticker
- MTVA
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2016-08-04
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- MTVA
Detail
Enriched 2026-08-14 20:47
- Market cap
- $7,591,623.9
- Shares outstanding (class)
- 5,164,370
- Shares outstanding (weighted)
- 5,164,370
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 8
- Location
- CAMBRIDGE, MA
- Homepage
- https://www.metaviatx.com
- Description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.